Hui Wang

Person

Hockessin, DE, US

People

Patents Grantslast 30 patents

Information Patent Grant
CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination...
- Patent number 12,060,433
- Issue date Aug 13, 2024
- Incyte Corporation
- Horacio G. Nastri
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION...
- Publication number 20250059293
- Publication date Feb 20, 2025
- INCYTE CORPORATION
- Horacio G. Nastri
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
- Publication number 20250041310
- Publication date Feb 6, 2025
- INCYTE CORPORATION
- Hui Wang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR
- Publication number 20230226040
- Publication date Jul 20, 2023
- INCYTE CORPORATION
- Alejandro Amador Arjona
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIB...
- Publication number 20220233529
- Publication date Jul 28, 2022
- INCYTE CORPORATION
- Hui Wang
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION...
- Publication number 20210230294
- Publication date Jul 29, 2021
- INCYTE CORPORATION
- Horacio G. Nastri
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
- Publication number 20210205311
- Publication date Jul 8, 2021
- INCYTE CORPORATION
- Hui Wang
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Person

Patents Grantslast 30 patents

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination...

Patents Applicationslast 30 patents

CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION...

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors

COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR

COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIB...

CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION...

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors